1-20 of 105
Gerard Lozanski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

CD123 As a Therapeutic Target in Accelerated and Blast Phase Myeloproliferative Neoplasms (MPNs)

Melissa Babcook, Gerard Lozanski, Sarah A Wall
Journal: Blood
Blood (2023) 142 (Supplement 1): 6346.
https://doi.org/10.1182/blood-2023-190244
Published: 2023
Journal Articles

Deconvoluting Clonal and Cellular Architecture in IDH -Mutant Acute Myeloid Leukemia

Maria Sirenko, Soobeom Lee, Zhengxi Sun, Ronan Chaligne, Georgios Asimomitis, Charlotte K Brierley, Elsa Bernard, Sheng F. Cai, Robert M Myers, Bettina Nadorp, Max F Levine, Dylan Domenico, Juan E Arango Ossa, Juan Santiago Medina Martinez, Kamal Menghrajani, Audrey Lasry, Alice Mims, Helee Desai, Andrea Laganson, Christopher Famulare, Minal Patel, Gerard Lozanski, Sanam Loghavi, Kelly L. Bolton, Aaron D. Viny, Mikhail Roshal, Ross L Levine, Eytan M. Stein, Dan A. Landau, Ann-Kathrin Eisfeld, Iannis Aifantis, Elli Papaemmanuil
Journal: Blood
Blood (2023) 142 (Supplement 1): 1591.
https://doi.org/10.1182/blood-2023-186322
Published: 2023
Journal Articles

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Kerry A Rogers, Eric McLaughlin, Lai Wei, Seema A Bhat, Arianna Crouse, Michael R. Grever, Dan Jones, Adam S Kittai, Gerard Lozanski, Mollie Moran, Mark Reid, Ellen J Sass, Swetha Suresh, John C. Byrd, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 1899.
https://doi.org/10.1182/blood-2023-180294
Published: 2023
Journal Articles

Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia

Kerry A Rogers, Qiuhong Zhao, Seema A Bhat, John C. Byrd, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Gerard Lozanski, Margaret S. Lucas, Lindsey Rike, Shanmugapriya Thangavadivel, William E. Carson III, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 3272.
https://doi.org/10.1182/blood-2023-180308
Published: 2023
Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Kyoko Yamaguchi, Salma Abdelbaky, Evgeny Arons, Matthew Cross, Yue-Zhong Wu, Christoph Weigel, Mirela Iulia Anghelina, Helen Parker, Artur Kibler, Marta Salido, Constance Regina Baer, Manja Meggendorfer, Benjamin Durham, Omar Abdel-Wahab, Seema A Bhat, Gerard Lozanski, Kerry A Rogers, Yonghong Wang, Paul S. Meltzer, Sunil Iyengar, Sascha Dietrich, Thorsten Zenz, James S. Blachly, Aurelie Verney, Lucile Baseggio, Alexandra Traverse-Glehen, Marc Seifert, Ralf Kuppers, Richard Burack, Clive S Zent, Versha Banerji, James B. Johnston, David Graham Oscier, Renata Walewska, Kostas Stamatopoulos, Torsten Haferlach, Ana Ferrer, Catherine Thieblemont, Francesco Forconi, Robert Kreitman, Michael R. Grever, Jonathan C. Strefford, Piers Blombery, Christopher C. Oakes
Journal: Blood
Blood (2023) 142 (Supplement 1): 174.
https://doi.org/10.1182/blood-2023-189835
Published: 2023
Journal Articles

Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Kerry A. Rogers, Eric McLaughlin, Lai Wei, Mirela Iulia Anghelina, Mir Khader Ali, Leslie A. Andritsos, Evgeny Arons, James S. Blachly, Timothy G. Call, S. Percy Ivy, Lacey James-Echenique, Jeffrey A. Jones, Robert J. Kreitman, Gerard Lozanski, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Michael R. Grever
Journal: Blood
Blood (2022) 140 (Supplement 1): 6494–6495.
https://doi.org/10.1182/blood-2022-165795
Published: 2022
Journal Articles

Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment

Andrew Stiff, Qiuhong Zhao, Nilesh Kapoor, Kerry A. Rogers, Mirela Iulia Anghelina, Jasmine Neal, Leslie A. Andritsos, James S. Blachly, Gerard Lozanski, Michael R. Grever, Seema A. Bhat
Journal: Blood
Blood (2022) 140 (Supplement 1): 6524–6525.
https://doi.org/10.1182/blood-2022-166619
Published: 2022
Journal Articles

Rate of Clonal Hematopoiesis in Patients with Venous Thromboembolism

Tamanna Haque, Arletta Lozanski, Tzyy-Jye Doong, Ying Huang, Rui Li, Abigail Bartosic, Gerard Lozanski, John C. Byrd, Tzu-Fei Wang
Journal: Blood
Blood (2021) 138 (Supplement 1): 4297.
https://doi.org/10.1182/blood-2021-151696
Published: 2021
Journal Articles

CD56 Has a Critical Role in Regulating Multiple Myeloma Cell Growth and Response to Therapies

Francesca Cottini, Jose Rodriguez, Maxwell Birmingham, Tiffany Hughes, Nidhi Sharma, Gerard Lozanski, Bei Liu, Yiping Yang, Emanuele Cocucci, Don M Benson, Jr.
Journal: Blood
Blood (2021) 138 (Supplement 1): 889.
https://doi.org/10.1182/blood-2021-146370
Published: 2021
Journal Articles

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison M Booth, Diane Feldman, Elie G Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla A. Heerema, Cecelia Miller, Gerard Lozanski, Richard F. Little, Brian T. Hill, Wei Ding, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 3728.
https://doi.org/10.1182/blood-2021-151471
Published: 2021
Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry Rogers, Sameer A. Parikh, Steven Coutre, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, James S. Blachly, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Jennifer R Brown, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 639.
https://doi.org/10.1182/blood-2021-153146
Published: 2021
Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Clinical Trials & Observations
Kerry A. Rogers, Leslie A. Andritsos, Lai Wei, Eric M. McLaughlin, Amy S. Ruppert, Mirela Anghelina, James S. Blachly, Timothy Call, Dai Chihara, Anees Dauki, Ling Guo, S. Percy Ivy, Lacey R. James, Daniel Jones, Robert J. Kreitman, Gerard Lozanski, David M. Lucas, Apollinaire Ngankeu, Mitch Phelps, Farhad Ravandi, Charles A. Schiffer, William E. Carson, III, Jeffrey A. Jones, Michael R. Grever
Journal: Blood
Blood (2021) 137 (25): 3473–3483.
https://doi.org/10.1182/blood.2020009688
Published: 2021
Includes: Supplemental data
Journal Articles

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Seema A Bhat, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Nyla A Heerema, PhD, Lynne V. Abruzzo, MD PhD, Cecelia Miller, PhD, Jennifer Zvosec, CCRP, Kasturi Ganesh-Barki, MBBS, John C. Byrd, MD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-138612
Published: 2020
Journal Articles

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, Corinne Hoffman, MS, CNP, Kami J. Maddocks, MD, Gerard Lozanski, MD, Adam S. Kittai, MD, Mollie E. Moran, Mark Reid, CNP, Jennifer A. Woyach, MD, John C. Byrd, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-137655
Published: 2020
Journal Articles

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, James S. Blachly, MD, Kerry A. Rogers, MD, Seema A Bhat, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Mojgan Jianfar, MD, Gerard Lozanski, MD, David M. Weiss, Barbara L. Andersen, PhD, Priti Patel, MD, Veerendra Munugalavadla, PhD, Anna Butturini, MD, Yan Xu, Min Hui Wang, PhD, John C. Byrd, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–18.
https://doi.org/10.1182/blood-2020-136317
Published: 2020
Journal Articles

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BT K/PLCG2 mutations

Fabienne Lucas, Karylin Larkin, C. Thomas Gregory, Shelley Orwick, Tzyy-Jye Doong, Arletta Lozanski, Gerard Lozanski, Shrilekha Misra, Apollinaire Ngankeu, Hatice Gulcin Ozer, Deepa Sampath, Shanmugapriya Thangavadivel, Selen A. Yilmaz, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach, James S. Blachly
Journal: Blood
Blood (2020) 135 (24): 2192–2195.
https://doi.org/10.1182/blood.2019003722
Published: 2020
Includes: Supplemental data
Journal Articles

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

Jennifer Woyach, MD, Ying Huang, MS, MA, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Arletta Lozanski, Tzyy-Jye Doong, James S. Blachly, MD, Gerard Lozanski, MD, Dan Jones, MD PhD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 504.
https://doi.org/10.1182/blood-2019-127674
Published: 2019
Journal Articles

Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer Woyach, MD, Amy S. Ruppert, MAS, PhD, Gabriela Perez, MS, Allison M Booth, Diane Feldman, Elie G Dib, MD, Aminah Jatoi, MD, Jennifer Le-Rademacher, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Richard Little, MD, Wei Ding, MD PhD, Brian T. Hill, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1751.
https://doi.org/10.1182/blood-2019-127102
Published: 2019
Journal Articles

Final Results of a Phase 2 Trial of Early Intervention Ibrutinib with Vaccinations in Patients with Asymptomatic, High-Risk CLL

Jennifer Woyach, MD, Shanmugapriya Thangavadivel, PhD, David Weiss, Lai Wei, PhD, Eric McLaughlin, MS, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Michael Keller, Matthew Dort, Gerard Lozanski, MD, Barbara Andersen, PhD, John C. Byrd, MD, Farrukh T. Awan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1759.
https://doi.org/10.1182/blood-2019-131099
Published: 2019